MARY LENORA DISIS
Osteopathic Medicine at Pacific St, Seattle, WA
License number
Washington MD00027334
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1959 NE Pacific St, Seattle, WA 98195
Phone
(206) 598-4100
(206) 543-6420
(206) 543-6420
Personal information
See more information about MARY LENORA DISIS at radaris.comName
Address
Phone
17850 SE 192Nd Dr, Renton, WA 98058
Renton, WA
17850 192Nd Dr, Renton, WA 98058
17850 SE 192Nd Dr, Renton, WA 98058
Professional information
See more information about MARY LENORA DISIS at trustoria.com
Dr. Mary L Disis, Seattle WA - MD (Doctor of Medicine)
Dr. Mary L Disis, Seattle WA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
(855) 557-0555 (Phone)
825 Eastlake Ave E, Seattle 98109
(855) 557-0555 (Phone)
Certifications:
Internal Medicine, 1989, Medical Oncology, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
University of Washington Medical Center
1959 East Pacific St, Seattle 98195
825 Eastlake Ave E, Seattle 98109
University of Washington Medical Center
1959 East Pacific St, Seattle 98195
Education:
Medical School
University of Nebraska / College of Medicine
Graduated: 1986
University Of Illinois
U Wash-Fred Hutchinson Cancer Ctr
University of Nebraska / College of Medicine
Graduated: 1986
University Of Illinois
U Wash-Fred Hutchinson Cancer Ctr
Immune Reactivity To Her-2/Neu Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
Immune Reactivity To Her-2/Neu Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
US Patent:
6664370, Dec 16, 2003
Filed:
Jul 15, 1999
Appl. No.:
09/354533
Inventors:
Martin A. Cheever - Mercer Island WA
Mary L. Disis - Renton WA
Mary L. Disis - Renton WA
Assignee:
University of Washington - Seattle WA
International Classification:
C07K 708
US Classification:
530328, 530326, 530300, 530350, 530403, 530402, 4241841, 4241851, 4242771, 514 2, 514 14, 514 15, 930 10
Abstract:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
Immune Reactivity To Her-2/Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Oncogene Is Associated
Immune Reactivity To Her-2/Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Oncogene Is Associated
US Patent:
7655239, Feb 2, 2010
Filed:
Jun 21, 2007
Appl. No.:
11/821574
Inventors:
Martin A Cheever - Mercer Island WA, US
Mary L Disis - Renton WA, US
Mary L Disis - Renton WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
A61K 38/08, C07K 7/06
US Classification:
4241851, 530300, 530327, 530328, 514 2, 514 15
Abstract:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
Immune Reactivity To Her-2/Neu Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
Immune Reactivity To Her-2/Neu Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
US Patent:
5846538, Dec 8, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/486348
Inventors:
Martin A. Cheever - Mercer Island WA
Mary L. Disis - Renton WA
Mary L. Disis - Renton WA
Assignee:
University of Washington - Seattle WA
International Classification:
A61K 3802, A61K 3900, C07K 14705, C07K 700
US Classification:
4241851
Abstract:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
Immune Reactivity To Her-2/Neu Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
Immune Reactivity To Her-2/Neu Protein For Diagnosis And Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
US Patent:
5726023, Mar 10, 1998
Filed:
Jun 6, 1995
Appl. No.:
8/467083
Inventors:
Martin A. Cheever - Mercer Island WA
Mary L. Disis - Renton WA
Mary L. Disis - Renton WA
Assignee:
University of Washington - Seattle WA
International Classification:
G01N 33536, G01N 33541, G01N 33566, C07K 1630
US Classification:
435 71
Abstract:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
Compounds For Eliciting Or Enhancing Immune Reactivity To Her-2/Neu Protein For Prevention Or Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
Compounds For Eliciting Or Enhancing Immune Reactivity To Her-2/Neu Protein For Prevention Or Treatment Of Malignancies In Which The Her-2/Neu Oncogene Is Associated
US Patent:
8524491, Sep 3, 2013
Filed:
Sep 4, 2009
Appl. No.:
12/554279
Inventors:
Martin A Cheever - Mercer Island WA, US
Mary L Disis - Renton WA, US
Mary L Disis - Renton WA, US
Assignee:
University of Washington through its Center for Commercialization - Seattle WA
International Classification:
C12N 15/12, C07H 21/02, C07H 21/04, C12N 15/63
US Classification:
4353201, 536 234, 536 235
Abstract:
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.
Mary Lenora Disis, Seattle WA
Mary Lenora Disis, Seattle WA
Specialties:
Oncologist
Address:
University Of Washington Medical Ctr, Seattle, WA 98195
815 Mercer St, Seattle, WA 98109
815 Mercer St, Seattle, WA 98109
Education:
University of Nebraska, College of Medicine - Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)*
Professor At University Of Washington
Professor At University Of Washington
Position:
Professor at University of Washington
Location:
Greater Seattle Area
Industry:
Higher Education
Work:
University of Washington
-
Professor
Diagnostic Panel Of Cancer Antibodies And Methods For Use
Diagnostic Panel Of Cancer Antibodies And Methods For Use
US Patent:
8216789, Jul 10, 2012
Filed:
Feb 27, 2009
Appl. No.:
12/394922
Inventors:
Mary L. Disis - Renton WA, US
Vivian Goodell - San Diego CA, US
Hailing Lu - Seattle WA, US
Vivian Goodell - San Diego CA, US
Hailing Lu - Seattle WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2/neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid.
Methods For Eliciting Or Enhancing Reactivity To Her-2/Neu Protein
Methods For Eliciting Or Enhancing Reactivity To Her-2/Neu Protein
US Patent:
5869445, Feb 9, 1999
Filed:
Apr 1, 1996
Appl. No.:
8/625101
Inventors:
Martin A. Cheever - Mercer Island WA
Mary L. Disis - Renton WA
Mary L. Disis - Renton WA
Assignee:
University of Washington - Seattle WA
International Classification:
A61K 3817
US Classification:
514 2
Abstract:
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.